CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Dexamethasone Sodium Phosphate

· ingredient dexamethasoneCorticosteroids· DEXAMETHASONE SODIUM PHOSPHATE 4 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.69334
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per ML — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other dexamethasone products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.

ProductNADAC / MLvs this
Dexamethasone$0.10682−$0.58650
Dexamethasone$0.15403−$0.53930
Dexamethasone$0.19895−$0.49440
TaperDex 12-day$0.19895−$0.49440
dexamethasone$0.20711−$0.48620
dexamethasone$0.25646−$0.43690
Dexamethasone Sodium Phosphate$0.69334+$0.00000
Dexamethasone Sodium Phosphate$0.69334+$0.00000

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.